8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist

• Heather Lin,
• Fei Yang,
• Siqing Fu,
• Joud Hajjar,
• Daniel Karp,
• Bettzy Stephen,
• Ignacio Wistuba,
• Yeonjoo Choi,
• Cheuk Hong Leung,
• Jordi Rodon,
• Edwin Parra,
• Naval Daver,
• Yali Yang

Affiliations

Heather Lin

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Fei Yang

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Siqing Fu

Aff3 grid.240145.60000000122914776University of Texas M.D. Anderson Cancer Center Houston TX USA

Joud Hajjar

Aff3 grid.416975.80000000122002638Section of Immunology, Allergy & Rheumatology, Baylor College of MedicineTexas Children’s Hospital 77030 Houston TX USA

Daniel Karp

Aff3 grid.240145.60000 0001 2291 4776Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA

Bettzy Stephen

Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ignacio Wistuba

Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Yeonjoo Choi

Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Cheuk Hong Leung

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Jordi Rodon

1MD Anderson Cancer Center, Houston, TX, USA

Edwin Parra

1MD Anderson Cancer Center, Houston, TX, USA

Naval Daver

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Yali Yang

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA